Sera Prognostics (SERA)

Executive Summary

Sera Prognostics, Inc. (NASDAQ: SERA) is a commercial-stage women's health diagnostics company focused on improving pregnancy outcomes through its proprietary proteomic-based preterm birth risk assessment test, PreTRM®. The company's mission is to provide physicians with actionable information to enable personalized prenatal care, potentially reducing the substantial health and economic burden associated with preterm birth. As of early 2026, Sera has achieved commercial launch with initial sales traction and has garnered positive clinical utility data supporting the use of PreTRM in routine prenatal screening. The company's strategy includes expanding payer coverage, building a direct sales force, and pursuing additional clinical indications to broaden its addressable market. With a current market valuation of approximately $78 million and a focused pipeline, Sera is positioned to address a significant unmet need in obstetrics, though adoption remains dependent on reimbursement expansion and clinical guideline inclusion.

Upcoming Catalysts (preview)

• Q3 2026Q3 2026 Earnings Report and Commercial Update75% success
• TBDMedicare Coverage Decision for PreTRM40% success
• Q4 2026Positive Data from Ongoing Prospective Outcomes Study60% success